Abstract
Continuous Manufacturing (CM) of pharmaceutical drug products is a new approach within the pharmaceutical industry. In the presented paper, a GMP continuous wet granulation line for production of solid dosage forms was investigated. The line was composed of the subsequent continuous unit: operations feeding – twin-screw wet-granulation – fluid-bed drying – sieving and tableting. The formulation of a commercial entity was selected for this study. Several critical process parameters were evaluated in order to probe the process and to characterize the impact on quality attributes. Seven critical process parameters have been selected after a risk analysis: API and excipient mass flows of the two feeders, liquid feed rate and rotation speed of the extruder and rotation speed, temperature and airflow of the dryer. Eight quality attributes were controlled in real time by Process Analytical Technologies (PAT): API content after blender, after dryer, in tablet press feed frame and of tablet, LOD after dryer and PSD after dryer (three PSD parameters: x10 x50 x90). The process parameter values were changed during production in order to detect the impact on the quality of the final product. The deep learning techniques have been used in order to predict the quality attribute (output) with the process parameters (input). The use of deep learning reduces the noise and simplify the data interpretation for a better process understanding. After optimization, three hidden layers neural network were selected with 6 hidden neurons. The activation function ReLU (Rectified Linear Unit) and the ADAM optimizer were used with 2500 epochs (number of learning cycle). API contents, PSD values and LOD values were estimated with an error of calibration lower than 10%. The level of error allow an adequate process monitoring by DNN and we have proven that the main critical process parameters can be identified at a higher levelof process understanding. The synergy between PAT and process data science creates a superior monitoring framework of the continuous manufacturing line and increase the knowledge of this innovative production line and the products that it makes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: European Journal of Pharmaceutics and Biopharmaceutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.